SK bioscienceLtd Second Quarter 2024 Earnings: ₩148 loss per share (vs ₩208 loss in 2Q 2023)

SK bioscienceLtd (KRX:302440) Second Quarter 2024 Results

Key Financial Results

• Revenue: ₩26.8b (up 1.1% from 2Q 2023).
• Net loss: ₩11.4b (loss narrowed by 29% from 2Q 2023).
• ₩148 loss per share (improved from ₩208 loss in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

SK bioscienceLtd Earnings Insights

Looking ahead, revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in South Korea.

Performance of the South Korean Biotechs industry.

The company's shares are up 6.1% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for SK bioscienceLtd that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.